Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Completed · Phase 1 · NCT04570267
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $70,173
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- CSL Behring
- Tested
- CSL324 (biological), Placebo (drug)
- Dates
- Started 2020-10-08; completion 2021-12-09
- Results posted
- Not yet
Study CSL324\_1003 is a single center, randomized, double-blind, placebo-controlled study designed to characterize and compare the PK properties and safety of a single subcutaneous dose of CSL324 in healthy Japanese and White subjects.
From ClinicalTrials.gov, last updated 2022-10-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $70,173 in research payments for this study in 2025 (16 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Rosmarin, MD Dermatology · Indianapolis, IN
- Wendy L. Mcfalda, D.O. Dermatology · Clarkston, MI
- Abel D. Jarell, MD Dermatology · Portsmouth, NH
- Brian Poligone, MD Dermatology · Fairport, NY
- Stephen M. Schleicher, M.D. Dermatology · Sugarloaf, PA
- William Abramovits, M.D. Dermatology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Allcutis Research LLC $21,700
- Universal Dermatology PLLC $16,000
- Michigan Center for Research Company $9,500
- Reveal Research Institute $9,223
- Best Skin Research $8,000
- Indiana University $5,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.